CCM
BIOL

Consonance Capital Management’s Biolase, Inc. BIOL Stock Holding History

Consonance Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-92
Closed -$1.12M – 22
2017
Q2 		$1.12M Sell
92
-9
-9% -$134K 0.13% 18
2017
Q1 		$1.7M Sell
101
-15
-13% -$272K 0.18% 22
2016
Q4 		$2.03M Sell
116
-27
-19% -$534K 0.22% 21
2016
Q3 		$3.13M Buy
143
+42
+42% +$748K 0.3% 21
2016
Q2 		$1.47M Buy
101
+1
+1% +$15.8K 0.21% 21
2016
Q1 		$1.64M Buy
100
+12
+14% +$151K 0.25% 20
2015
Q4 		$922K Sell
88
-4
-4% -$43.7K 0.12% 20
2015
Q3 		$1.04M Buy
92
+39
+74% +$725K 0.15% 25
2015
Q2 		$1.16M Buy
+53
New +$1.29M 0.12% 27

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
TA
Teton Advisors Rye, New York $173M AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return

Consonance Capital Management's BIOL Position: Q3 2017 in Review

Consonance Capital Management sold out of Biolase, Inc. (BIOL) in Q3 2017, closing a stake of 92 shares — an estimated $1.12M sold.

Consonance Capital Management first reported a position in BIOL in Q2 2015 and held it in 9 quarters. The position peaked at $3.13M in Q3 2016. 28 funds tracked by Wall St. Rank hold BIOL as of Q3 2017.

  • Consonance Capital Management reported no remaining Biolase, Inc. position as of Q3 2017 after selling out during the quarter.
  • Consonance Capital Management sold 92 Biolase, Inc. shares in Q3 2017, an estimated $1.12M.
  • Consonance Capital Management first reported a position in Biolase, Inc. in Q2 2015 and held it in 9 quarters.
  • Consonance Capital Management's Biolase, Inc. position peaked at $3.13M in Q3 2016.
  • 28 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2017.

Based on Consonance Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.